LENZ Therapeutics, Inc. expected to post a loss of 91 cents a share - Earnings Preview

What happened

LENZ Therapeutics is expected to report a 66.4% revenue decrease to $4.2 million from $12.5 million a year earlier, and a loss of 91 cents a share, when it reports on October 29 for the quarter ending September 30, 2026.

Confirmed

Global impact / market context

A much smaller revenue base alongside a per-share loss means the company is likely spending more than it brings in, so investors will focus on whether cash on hand can fund operations until revenue recovers.

Analyst inference

Analysts rate the shares a buy on average, and the median 12-month price target of $10.00 sits about 218% above the last close of $3.15, suggesting the market is pricing doubt that the company meets expectations.

Analyst inference

What to watch

1. The company reports results on October 29 for the quarter ending September 30, 2026, with the mean estimate from 7 analysts pointing to a loss of 91 cents per share. Confirmed
2. Watch whether management gives any plan to stabilize revenue or cut costs, since no such proposal appears in the supplied text and only the reported figures are known. Proposed
3. Because the mean earnings estimate was unchanged over three months, any larger loss could push analysts to lower targets, while a smaller loss could support the current buy ratings. Analyst inference

Affected assets

• SOL — Solana

Evidence

• Original source link unavailable